

FORM PTO-1390
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

7397-3

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/018260

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO.
PCT/GB00/02117INTERNATIONAL FILING DATE
June 12, 2000PRIORITY DATE CLAIMED
June 10, 1999**TITLE OF INVENTION**
HEPARANASE ASSAY**APPLICANT(S) FOR DO/EO/US**
Paul Ernest Charles Brenchley

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English lanugage translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).


Items 11 to 20 below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
14. A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. A substitute specification.
16. A change of power of attorney and/or address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information:

International Preliminary Examination Report

"Express Mail" label number EL683237701US. Date of Deposit Dec. 7, 2001 I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Neil Mercer

U.S. APPLICATION NO. (if known, see 37 CFR 1.15)	INTERNATIONAL APPLICATION NO. PCT/GB00/02117	ATTORNEY'S DOCKET NUMBER 7397-3																
<p><input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1040.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p>		CALCULATIONS PTO USE ONLY																
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 890.00																
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">CLAIMS</th> <th style="width: 25%;">NUMBER FILED</th> <th style="width: 25%;">NUMBER EXTRA</th> <th style="width: 25%;">RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>20 - 20 = 0</td> <td>x \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent claims</td> <td>2 - 3 = 0</td> <td>x \$84.00</td> <td>\$</td> </tr> <tr> <td>MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td></td> <td>+ \$280.00</td> <td>\$</td> </tr> </tbody> </table>		CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	20 - 20 = 0	x \$18.00	\$	Independent claims	2 - 3 = 0	x \$84.00	\$	MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$280.00	\$	TOTAL OF ABOVE CALCULATIONS =
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE															
Total claims	20 - 20 = 0	x \$18.00	\$															
Independent claims	2 - 3 = 0	x \$84.00	\$															
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$280.00	\$															
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		\$ +																
SUBTOTAL =		\$ 890.00																
<p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 75%;">TOTAL NATIONAL FEE</th> <th style="width: 25%;">=</th> </tr> </thead> <tbody> <tr> <td style="text-align: right;">Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property , +</td> <td style="text-align: right;">\$ 890.00</td> </tr> </tbody> </table>		TOTAL NATIONAL FEE	=	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property , +	\$ 890.00	TOTAL FEES ENCLOSED =												
TOTAL NATIONAL FEE	=																	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property , +	\$ 890.00																	
		<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 75%; text-align: right;">Amount to be refunded:</td> <td style="width: 25%; text-align: right;">\$</td> </tr> <tr> <td colspan="2" style="text-align: right;">charged:</td> <td style="text-align: right;">\$</td> </tr> </table>	Amount to be refunded:	\$	charged:		\$											
Amount to be refunded:	\$																	
charged:		\$																
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$ 890.00</u> to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-3030</u>. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>																		
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</p>																		
<p>SEND ALL CORRESPONDENCE TO:</p> <p>Thomas Q. Henry Woodard, Emhardt, Naughton, Moriarty & McNett 111 Monument Circle 3700 Bank One Tower Indianapolis, IN 46204</p>																		
 SIGNATURE Thomas Q. Henry <hr/> NAME 28, 309 <hr/> REGISTRATION NUMBER																		

10/018260
JC05 Rec'd PCT/PTO 07 DEC 2001

7397-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:) Express Mail No. EL683237701US
Paul Ernest Charles Brenchley)
Serial No. (unknown))
Filed Herewith)
HEPARANASE ASSAY)
US National Stage of PCT/GB00/02117)
International Filing Date June 12, 2000)

PRELIMINARY AMENDMENT

Hon. Assistant Commissioner of Patents

Washington, D.C. 20231

Sir:

Please enter the following Preliminary Amendment in the above-identified patent application. The Commissioner is hereby authorized to charge payment of any additional fees associated with this application or credit any overpayment to Deposit Account No. 23-3030.

IN THE CLAIMS

Please amend claims 3, 6, 7, 9, 11, 13, 15, 19 and 20 as follows.

Clean copy of the Claims As Amended

1. A method of assaying a sample to determine heparanase activity thereof the method comprising
- (i) incubating the sample in the presence of a first solid phase support having immobilised thereon an HSGAG polymer substrate for the heparanase, the said substrate being insensitive to the action of proteases and the said substrate having bonded thereto a first binding moiety and having further bonded thereto a paracrine cell regulator capable of binding to HSGAG,
 - (ii) treating the incubated sample with a second solid phase support having a second moiety provided thereon capable of immobilising HSGAG polymer substrate cleaved from the first solid phase support on said second solid phase support by binding of said second moiety either with the paracrine cell regulator or with the first binding moiety,
 - (iii) generating a measurable signal the other of the first or second moiety of the cleaved substrate immobilised in the second support solid phase, and
 - (iv) measuring the signal on the second solid phase support separated from the first solid phase support.
2. A method as claimed in claim 1 wherein the HSGAG polymer substrate is covalently bonded to the first solid phase support system.
3. A method as claimed in claim 1 wherein the first solid phase support system is a microtitre well.
4. A method as claimed in claim 3 wherein the second solid phase support system is a plate lid probe.

5. A method as claimed in claim 3 wherein the second solid phase support system is a microtitre well.
6. A method as claimed in claim 1 wherein the second solid phase support system is separated from the first solid phase support system between steps (ii) and (iii).
7. A method as claimed in claim 1 wherein, in step (ii), HSGAG polymer substrate cleaved from the first solid phase support is immobilised in the second solid phase support by binding of the first and second moieties.
8. A method as claimed in claim 7 wherein the first moiety is biotin and the second moiety is strept(advin).
9. A method as claimed in claim 7 wherein the signal is generated by an anti- paracrine cell regulator antibody and enzyme coupled anti-species antibody.
10. A method as claimed in claim 9 wherein the signal is developed by incubating the second solid phase support with anti- paracrine cell regulator antibody followed by peroxidase anti-species IgG.
11. A method as claimed in claim 1 wherein, in step (ii), the HSGAG polymer substrate cleaved from the first solid phase support is immobilised on the second solid phase support by binding of the paracrine cell regulator and the first moiety.
12. A method as claimed in claim 11 wherein the signal is generated by an enzyme coupled to a third moiety capable of binding to the first moiety.
13. A method as claimed in claim 1 wherein the paracrine cell regulator is a growth factor, a cytokine or a chemokine.

14. A method as claimed in claim 13 wherein the paracrine cell regulator is a growth factor and is selected from VEGF, TGF β 1, FGF-1, FGF-2, HGF, PDGF, IL-1 α , IL-1 β , IL-2, IL-4, IL-7, IL-8, IL-12, IP-10, MCP-1, TNF α or IFN- α .
15. A method as claimed in claim 1 for determining the activity of a putative inhibitor of heparanase activity.
16. A solid phase support having immobilised thereon an HSGAG polymer substrate having bonded thereto a first binding moiety and a paracrine cell regulator capable of binding to HSGAG, said first moiety or said paracrine cell regulator being capable of binding to a second moiety.
17. A support as claimed in claim 16 wherein the paracrine cell regulator is a growth factor, chemokine or cytokine.
18. A support as claimed in claim 17 wherein the paracrine cell regulator is selected from VEGF, TGF β 1, FGF-1, FGF-2, HGF, PDGF, IL-1 α , IL-1 β , IL-2, IL-4, IL-7, IL-8, IL-12, IP-10, MCP-1, TNF α or IFN- α .
19. A support as claimed in claim 16 wherein the first moiety is biotin.
20. The combination of a solid phase support as claimed in claim 16 and a second solid phase support having provided thereon said second moiety.

Version with Markings to Show Changes Made

3. A method as claimed in claim 1 or 2 wherein the first solid phase support system is a microtitre well.
6. A method as claimed in any of claims 1 to 5 wherein the second solid phase support system is separated from the first solid phase support system between steps (ii) and (iii).
7. A method as claimed in any one of claims 1 to 6 wherein, in step (ii), HSGAG polymer substrate cleaved from the first solid phase support is immobilised in the second solid phase support by binding of the first and second moieties.
9. A method as claimed in claim 7 or 8 wherein the signal is generated by an anti- paracrine cell regulator antibody and enzyme coupled anti-species antibody.
11. A method as claimed in any one of claims 1 to 6 wherein, in step (ii), the HSGAG polymer substrate cleaved from the first solid phase support is immobilised on the second solid phase support by binding of the paracrine cell regulator and the first moiety.
13. A method as claimed in any one of claims 1 to 12 wherein the paracrine cell regulator is a growth factor, a cytokine or a chemokine.
15. A method as claimed in any of claims 1 to 14 for determining the activity of a putative inhibitor of heparanase activity.
19. A support as claimed in any one of claims 16 to 18 wherein the first moiety is biotin.
20. The combination of a solid phase support as claimed in any one of claims 16 to 19 and a second solid phase support having provided thereon said second moiety.

REMARKS

Consideration and allowance of the above application is requested.

Respectfully submitted,

By:



Thomas Q. Henry
Reg. No. 28,309
Woodard, Emhardt, Naughton
Moriarty & McNett
Bank One Center/Tower
111 Monument Circle, Suite 3700
Indianapolis, IN 46204-5137
(317) 634-3456

PBA/NE/D088414PUS:TQH:151126

WO 00/77241

1/PRT.

PCT/GB00/0217 10/018260
JC05 Rec'd PCT/PTO 07 DEC 2001HEPARANASE ASSAY

The present invention relates to an assay for heparanase activity

Endoglycosidases are capable of cleaving polymers comprised of glycosaminoglycan units (so called "GAG polymers"). Enzymes that cleave a GAG polymer internally are known as endoglycosidases and include heparanase which cleaves heparan sulphate GAG, hyaluronidase which cleaves hyaluronic acid GAG and chondroitinase which cleaves chondroitin sulphate GAG.

Heparanase has been described in T&B lymphocytes, monocytes, neutrophils, platelets, endothelial cells and in liver and placental tissue. This endoglycosidase activity which degrades heparan sulphate GAG has been variously called heparanase, heparinase, heparitinase and heparan sulphate lyase and almost certainly represents a family of enzymes with different specificities for the internal cleavage site in the GAG polymer.

Heparan sulphate glycosaminoglycans (HSGAGS) of which heparin, the anticoagulant is an example, are highly N- and O-sulphated carbohydrate polymers of glucuronic (sometimes iduronic) acid and glucosamine (sometimes N-acetylated). The high anionic charge is not randomly distributed throughout the polymer but is thought to form clusters of charged residues imparting specific functional binding properties to the sequence. This is demonstrated by the most important anti-coagulant properties of the pentasaccharide sequence in heparin and its interaction with anti-thrombin III..

HSGAG is present in the extracellular matrix, in basement membranes and on cell surfaces. HSGAG is known to play an important role in linking the component structural proteins of the basement membrane, controlling the permeability properties of the membrane (best illustrated in the glomerular basement membrane) and controlling the bio-availability of cytokines and growth factors.

WO 00/77241

PCT/GB00/02117

2-

Heparanases are known to play important roles in areas of discovery biology

- a) cancer metastasis; the most metastatic cells display the highest levels of heparanase enzyme which may enable cancer cells to degrade HSGAG in ECM and basement membranes to facilitate tissue invasion. Cancer cells secreting heparanase may support angiogenesis, tumour vascularisation and therefore tumour growth. This is a prime area for developing novel antagonists to heparanase as part of a therapeutic strategy to suppress and inhibit metastasis.
- b) in inflammatory joint disease e.g. rheumatoid arthritis; angiogenesis in the joint may support the chronic inflammatory pathology. Agents inhibiting heparanase in the joint may reduce angiogenesis and therefore suppress the formation of the inflammatory pannus of tissue which causes degradation of cartilage and erosion of bone.
- c) in proteinuric disease; HSGAG expression within the glomerular basement membrane controls the passage of anionic charged proteins e.g. albumin. In early diabetic nephropathy there is evidence of reduced basement membrane HSGAG associated with microalbuminuria. Furthermore, a number of clinical and experimental studies document reduction in proteinuria associated with low molecular weight heparin treatment. These findings support the role of increased heparanase expression within the glomerulus which might be treated with suitable antagonists.

Known assays (summarised below) for heparanase activity have a number of disadvantages.

(i) Radiolabelled substrate.

In vitro metabolic radiolabelling of cell cultures with $^{35}\text{SO}_4$ or ^3H incorporated into HSGAG is commonly used for detecting heparanase. The radiolabelled GAG

may be used following isolation and purification by coupling to a solid phase support. Alternatively, radiolabelled ECM laid down on culture dishes with the cell layer removed, may be used as substrate. Alternatively, ³H or ¹²⁵I labelling of purified HSGAG or heparin is performed and the labelled substrate coupled to a solid phase. Heparanase activity is detected by loss of radiolabel and or reduction in molecular size of labelled species.

The radiolabelling procedures are hazardous and require special disposal procedures. Large variations in specific activity of substrate occur between batches. The batches of ³⁵SO₄ substrate have a short lifetime of 2 to 3 months.

(ii) HS Substrate showing sensitivity to other enzymes

Assays claiming to measure heparanase that use heparan sulphate proteoglycan as the substrate and detect apparent enzyme activity by identifying release of labelled HSGAG or a reduction in the size profile of HSGAG (using isotope or other label) by molecular sieving are not specific for heparanase. A wide range of proteases present in the sample could act on the proteoglycan component to solubilise significant quantities of HS chains and cause reduction in size by further removal of attached protein. Other enzymes e.g. hyaluronidase may cleave the substrate. Few current assays have demonstrated insensitivity to this range of enzymes.

(iii) Sensitivity and quantitation

Assays requiring long incubation times (4-24 hours) to achieve an effect indicate a lack of sensitivity and leave open the possibility of interference by non-specific factors (e.g. proteases).

Assays requiring molecular sieving to identify the outcome of heparanase activity are only qualitative in nature

SEARCHED INDEXED
SERIALIZED FILED

(iv) Multiple sample handling

Assays requiring centrifugation or molecular sieving to separate the products of heparanase activity only allow small batch assays to be performed.

. It is an object of the present invention to obviate or mitigate the above mentioned disadvantages.

According to a first aspect of the present invention there is provided a method of assaying a sample to determine heparanase activity thereof the method comprising

- (i) incubating the sample in the presence of a first solid phase support having immobilised thereon an HSGAG polymer substrate for the heparanase, the said substrate being insensitive to the action of proteases and the said substrate having bonded thereto a first binding moiety and having further bonded thereto a paracrine cell regulator capable of binding to HSGAG,
 - (ii) treating the incubated sample with a second solid phase support having a second moiety provided thereon capable of immobilising HSGAG polymer substrate cleaved from the first solid phase support on said second solid phase support by binding of said second moiety either with the paracrine cell regulator or with the first binding moiety,
 - (iii) generating a measurable signal the other of the first or second moiety of the cleaved substrate immobilised in the second support solid phase, and
 - (iv) measuring the signal on the second solid phase support separated from the first solid phase support.

卷之三

In a second aspect, the invention provides, for the use in an assay as defined above, a solid phase support (equivalent to the aforementioned first support) having immobilised thereon an HSGAG polymer substrate for heparanase, said substrate having bonded thereto a first binding moiety and having further bonded thereto a paracrine cell regulator capable of binding to HSGAG, said first moiety or said paracrine cell regulator being capable of binding to a second moiety.

In a third aspect, the invention provides the combination of first solid phase support as defined in the previous paragraph and second solid phase support having provided thereon a second moiety capable of binding to either the first moiety or the paracrine cell regulator to form a complex therewith.

In a fourth aspect, the invention provides an assay kit comprising the combination of the previous paragraph and signal developing agents to generate a signal representative of the result of the assay.

The paracrine cell regulator may, for example, be a growth factor, cytokine or chemokine.

The assay of the invention allows rapid quantitation of heparanase activity in a sample having, or potentially containing, such activity.

The invention is further described with reference to the paracrine cell regulator being an HSGAG binding growth factor but it is to be understood that the invention is equally applicable to other paracrine cell regulators.

The assay is conducted using a solid phase format. Step (i) of the assay uses a first solid phase support on which is immobilised an HSGAG polymer substrate which is cleavable by the heparanase present (or potentially present) in the sample. Bonded to this polymer substrate are

- (a) HSGAG binding growth factor, and

DOCUMENT CODED

WO 00/77241

PCT/GB00/02117

(b) a first binding moiety

The HSGAG substrate bonded to the support is insensitive to the action of proteases at concentrations normally found in clinical samples (otherwise the assay would give a false positive result). This may be achieved by ensuring that the HSGAG substrate is bonded to the first solid phase support otherwise than via any residual small peptide chain in the substrate derived from the proteoglycan from which the HSGAG substrate has been purified. For this purpose, the procedure of immobilising the HSGAG substrate on the support may involve oxidation of the sugar residue of the substrate (e.g. using periodate as described in the experimental protocol described *infra*).

Given that there is heparanase activity in the sample, the procedure of step (i) results in cleavage of HSGAG polymer substrate in an amount which is dependent on the degree of heparanase activity in the sample and its ability to cleave the HSGAG polymer substrate in the presence of the growth factor bonded thereto.

Any cleaved HSGAG polymer substrate (having both the first moiety and the growth factor bonded thereto) is released into the analyte phase. Confirmation that HSGAG-growth factor has been removed from the solid phase in step (i) can be obtained after step (ii) by incubating the washed heparanase treated solid phase with (strept)avidin-conjugated enzyme or anti-growth factor conjugated enzyme and comparing the signal with that obtained from a control solid phase. Heparanase activity significantly reduces the signal obtained.

In step (ii), the analyte phase is treated with a second solid phase support system incorporating a second moiety capable either of forming a complex with the first binding moiety or capable of forming a complex with the growth factor. As a result, complex formation between the first and second moieties occurs or complex formation between the growth factor and the second moiety occurs resulting in the cleaved fragments becoming immobilised on the second solid phase support. Either

the first moiety or the growth factor remains unbound and is used for signal development.

In step (iii), a measurable signal is generated from the cleaved fragments immobilised on the second solid phase support. The signal may be dependent on the growth factor component of the complex (where the complex is captured by the first binding moiety and detected with anti-growth factor antibody) and enzyme coupled anti-species antibody. Alternatively, where the complex is captured by anti-growth factor antibody the signal may be generated by an enzyme coupled to a third moiety capable of binding to the first moiety. The signal may for example, be a colorimetric signal and be measured by a spectrophotometer. Alternatively the signal may be a fluorescent signal which facilitates automation of the assay with high throughput.

Finally in step (iv), the signal generated in step (iii) is measured. This measurement is effected with the second solid phase support system separated from the first such system (i.e. that employed in step (i)) so that the signal is measured otherwise than in the environment of said first such system.

The measured signal is representative of the specific heparanase activity in the original sample. More particularly, the measured signal directly reflects the biological action in generating complexes of growth factor-HSGAG that would be produced in physiological and pathological states.

A critical control point in these pathologies is the bioavailability of important cytokine, chemokine and growth factors. On release from the secreting cell, most of the mediator(>70%) would normally interact with HSGAG in extracellular matrix (ECM) to form a stable reservoir of mediator. Only a fraction of the secreted mediator directly and immediately binds to the specific mediator receptor on the target cell to initiate cell signalling. Heparanase enzymes provide critical control of this reservoir

WO 00/77241

PCT/GB00/02117

by releasing these biologically specific growth factors from ECM that can bind their target receptors and initiate signalling.

Cytokines that bind HSGAG include IL-1 α and IL-1 β , IL-2, IL-4, IL-7, IL-8, IL-12, TNF α , IFN α . Chemokines that bind HSGAG include IP-10, MCP-1. Growth factors that bind HSGAG include VEGF, FGF-1, FGF-2, TGF β 1, PDGF, HGF. The term growth factor will be used to denote any of these mediators. The invention will measure heparanase activity using any of these heparan sulphate binding GFs.

The heparanase-released growth factor in the form of a complex of variable length of HSGAG sequence bound to growth factor may be significantly more active biologically than the native growth factor.

The binding sites in HSGAG that interact with these growth factors are poorly described at present and it may be that each growth factor has a unique binding site. Alternatively, some growth factors may share a certain binding sequence in HSGAG.

Heparanases from different cell sources may be differentiated from each other by their ability to solubilise particular growth factors or combinations of growth factors from HSGAG. This will happen where the binding of growth factor to the HSGAG substrate protects or sterically occludes a potential enzyme cleavage site. Thus by use of a panel of growth factors bound to HSGAG, it may be possible to attribute a particular pattern of GF solubilisation to a heparanase from platelets compared to synovial fluid or tumour. This may be of importance for instance in differentiating the action of a tumour heparanase from platelet derived heparanase.

Of considerable importance in the design of antagonists of heparanase function is the use of this method to generate selective heparanase inhibitors of exquisite specificity such that inhibition is confined to those HSGAG cleavage sites linked with solubilisation of a certain growth factor. Thus, for instance, a specific inhibitor of VEGF solubilisation may reduce and suppress tumour angiogenesis and

metastasis without inhibiting the immune functions of a platelet heparanase in solubilising IFN α to protect from infection during wound healing.

The assay is unaffected by the presence of proteases, hyaluronidase and chondroitinases. The assay is sensitive only requiring incubation times at step (i) of 30-60 minutes.

The method of the invention may be used for determining heparanase activity in a biological sample, e.g. for the purposes of diagnosing or characterising a particular medical condition. It is however envisaged that an important application of the invention will be in the screening of potential inhibitors or enhancers of heparanase activity. Thus, for example, the assay may be conducted with an analyte containing an heparanase and a putative inhibitor therefore to determine the effect (or otherwise) of that inhibitor.

Preferred embodiments of the Invention will now be described.

The assay of the invention is particularly useful for determining heparanase activity, e.g. for the purpose of evaluating potential inhibitors thereof.

The GAG polymer substrate immobilised on the support is preferably heparan sulphate glycosaminoglycan.

The first solid phase support system (i.e. the system in which the HSGAG polymer substrate is immobilised) is preferably a microtitre well. The assay may be conducted using a tray of microtitre wells or larger arrays having immobilised HSGAG polymer substrate. As such, the assay of the invention may be effected using robotic technology to screen compounds for anti-heparanase activity. When using a microtitre well as the first support system, the second solid phase support system may be a microtitre plate lid with a coated probe extending into each assay well as the second support system, for example, NUNC® TSP screening system or FALCON® FAST system. In this case, step (i) and step (ii) of the assay take place during the

10030866 - 01452002

WO 00/77241

PCT/GB00/02117

same incubation time. Alternatively, the second solid phase may be another coated microtitre well and step (i) and step (ii) occur sequentially and require physical transfer of the contents of the first well to the second well.

If the cleaved substrate is to be captured (on the second solid phase support) by the first moiety then the first moiety may be biotin and the second moiety streptavidin. In this case the signal may be generated by means of an anti-growth factor antibody and enzyme coupled anti-species antibody.

If the cleaved substrate is to be captured by the growth factor then the second moiety may be anti-growth factor antibody. In this case the first moiety may be biotin and the signal generated by an enzyme coupled to (strept)advin (as the aforementioned third moiety).

The method of the invention may be effected using the following protocol.

The GAG polymer substrate may be tagged with biotin using simple photobiotylation chemistry. A mixture of photobiotin (1mg/ml) and HSGAG (10mg/ml) in phosphate buffered saline (PBS) at a ratio of 2:1 (vol/vol) is exposed to UV light emitted from a Mercury arc HBO50 W lamp used as a microscope UV source for 21 minutes at a distance of 10 cm. The biotinylated HSGAG is dialysed against PBS for 18 hours at 4°C and stored at -20°C.

The immobilisation of the GAG polymer substrate on the solid phase support is carried out after the tagging with the first complex forming moiety and may be effected by oxidising the substrate with periodate and incubation with carbohydrate binding multiwell plates (for example, COSTAR® or NUNC plates may be used) to yield a surface to which the substrate is covalently and stably bonded. Specifically, sodium periodate at 10µM and biotinylated HSGAG at 5µg/ml in sodium acetate buffer (10mM, pH 4.0) are allowed to interact for upto 15 minutes and then 100µl of the activated biotinylated HSGAG is added to each well of the carbohydrate binding assay plate for 1 hour, shaking at 37°C. The plates are then washed thoroughly in

WO 00/77241

PCT/GB00/02117

11]-

PBS containing 0.1% Tween® 20. 100 μ l of 1% bovine serum albumin (BSA) in PBS is added to each well and incubated at 37°C for 60 minutes to block any nonspecific binding sites on the plate. Following washing with PBS, the coated plate may be used immediately or stored wrapped in cling film at 4°C for several months.

Once the GAG polymer substrate has been immobilised in the first support, it (i.e. the substrate) may be treated with a GAG binding growth factor (e.g. VEGF, TGF β 1, MCP-1, IFN- γ , see list in claim 8). 100 μ l of GF at 1-5 μ g/ml in PBS is added to each well and incubated for 18 hours at 4°C. Following washing in PBS, the plate is ready for use.

The second solid phase support may be prepared by coating the support material with the second complex forming moiety (e.g. (strep)avidin blocked with BSA). The microwell lid probes or wells, where the second solid phase is another well, are coated with (strept)avidin at 1.5 μ g/ml in PBS for 18 hours and following washing in PBS they are blocked with BSA as above.

To carry out the assay, the analyte having (or potentially having) heparanase activity is incubated in the presence of the first solid phase support system. The analyte is diluted in enzyme assay buffer which is sodium acetate (0.1M, pH 5.5 containing Ca^{2+} (5mM), Cu^{2+} (1mM) and Fe^{3+} (1mM). Each assay includes as controls, wells without biotinylated HSGAG coating and wells which do not receive the test sample. The heparanase assay is allowed to proceed for 1 hour normally (but may range from 30minutes to 4 hours) on a plate shaker at 37°C. Where the second solid phase is a well lid coated probe, steps (i) and (ii) occur simultaneously, where the second solid phase is another coated well, the supernatant from the first well is transferred to the second well and incubated for 2 to 24 hours.

As a result, any biotinylated HSGAG-GF substrate cleaved from the first solid phase support during incubation becomes immobilised on the second support which may now be separated from the analyte.

WO 00/77241

PCT/GB00/02117

12

A signal is then developed. Where the second solid phase used strep(avidin) to capture the complex through its biotin moiety, this may be achieved by incubating the second solid phase support with anti-growth factor antibody followed by enzyme-conjugated anti-species IgG. Where the second solid phase used anti-growth factor antibody to capture the complex, signal may be developed by incubating with enzyme-conjugated strep(avidin). Confirmation that the substrate bound to the first solid phase has been cleaved can be obtained by incubation with either enzyme conjugated strep(avidin) or enzyme conjugated antibody. The preferred enzyme conjugated to these detection reagents is peroxidase and therefore the amount of peroxidase activity associated with the well probe may be revealed using a standard TMB substrate colour change and spectrophotometry.

The invention will be illustrated by the following non-limiting Example and References Examples and the accompanying drawings which illustrate the results of Reference Examples 1 and 2.

Reference Example 1

This Reference Example demonstrates the specificity of biotinylated HSGAG for heparanase.

Biotinylated HSGAG was prepared using the procedure described in the above protocol and immobilised on microtitre wells as the solid phase support, again using the procedure of the protocol

Separate samples of the support-bound biotinylated HSGAG were incubated for 1 hour at 37 °C with a number of enzymes at very high concentrations (> 100 fold than would be encountered in clinical samples) including proteases e.g. dispase, thrombin, collagenase, trypsin, plasmin, pepsin and glycosidase e.g. neuraminidase and endoglucuronidases e.g. heparanase, hyaluronidase and chondroitinase at the initial concentrations shown in the following Table 1.

TABLE I

Enzyme	Initial Concentration
Heparanase	Spleen extract (neat)
Hyaluronidase	25mg/ml
Dispase	1mg/ml
Thrombin	250U/ml
Collagenase	1mg/ml
Trypsin	1mg/ml
Plasmin	1U/ml
Pepsin	1mg/ml
Chondroitinase	5U/ml
Neuraminidase	1mg/ml

After the initial incubation period, the % release of HSGAG was determined by the following procedure. 100 μ l of avidin peroxidase at 1:1000 dilution in PBS was added to the plate for 60 mins at 37 °C. After washing three times in PBS Tween, 100 μ l of TMB substrate (100 μ g/ml) was added and the colour development was assayed in end point mode at 450nm after stopping the reaction with 100 μ l of 0.1M HCl.

The above procedure was repeated for all the above enzymes using dilution factors of 400 and 800 as compared to its initial concentration.

The results are plotted in Fig 1 of the accompanying drawings.

The plot of Fig 1 clearly demonstrates the specificity of the biotinylated HSGAG for Heparanase.

Only Hyaluronidase, Dispase and Thrombin appeared to have a minor effect on the substrate which in the case of dispase and thrombin disappeared with dilution (Fig 1). Collagense, Trypsin, Plasmin, Pepsin, Chondroitinase and Neuraminidase

WO 00/77241

PCT/GB00/02117

14-

had no discernable effect on the substrate with % release for these enzymes too low to be plotted on the graph..

Reference Example 2

This Reference Example demonstrates that support-bound biotinylated HSGAG is cleaved from the solid phase by heparanase treatment.

Samples of biotinylated HSGAG immobilised on solid phase were prepared as in the above described protocol.

A dilution series of spleen extract of heparanase was prepared, added to separate samples of the support-bound HSGAG substrate and incubated for 60 minutes.--The support was then washed followed by addition of avidin peroxidase 1:1000 for 30-60 minutes at 37 ° C. Peroxidase substrate TMB 100ug/ml was added and colour change measured by spectrophotometry.

The results are plotted in Fig 2 which demonstrates that loss of biotinylated HSGAG was proportional to heparanase dilution over two orders of magnitude.

Reference Example 3

This Reference Examples demonstrates that a complex of HSGAG and Growth factor can be cleaved from the solid phase.

Biotinylated HSGAG prepared as in the above described protocol was immobilised on a solid support using the procedure of the above described protocol.

Recombinant growth factor/cytokine (63ng/ml in PBS) was incubated in the wells overnight to allow binding to the HSGAG and form a solid phase bound complex. Unbound GF/cytokine was removed by washing three times with PBS.

CONFIDENTIAL

WO 00/77241

PCT/GB00/02117

A standard dilution 1:20 of spleen heparanase enzyme was added to the wells for one hour and the amount of GF/cytokine remaining was detected by use of a specific anti-GF/cytokine antibody. This antibody was detected by an anti-species peroxidase coupled reagent followed by substrate development.

The results were as shown in the following Table 2.

Growth Factor/Cytokine	% reduction in GF after heparanase treatment
VEGF	68.7
IFN γ	73.7
MCP-1	81.2
TGF β 1	79.9

The results demonstrate cleavage of the complex of HSGAG and GF/cytokine from the solid phase by the heparanase.

Example 1.

This Example demonstrates detection of biotinylated HSGAG-Growth factor complexes.

Biotinylated HSGAG prepared as in the above described protocol was immobilised on a solid support, again using the procedure of the protocol.

Recombinant VEGF (63 ng/ml in PBS) was incubated in the wells overnight to allow binding to the HSGAG and form a solid phase bound complex of the HSGAG and VEGF.

Unbound VEGF was removed by washing three times with PBS.

Heparanase enzyme from spleen at 1:10 dilution was added to the wells for one hour. Subsequently the well contents were transferred to another ELISA plate.

WO 00/77241

PCT/GB00/02117

precoated with monoclonal anti-VEGF antibody (5 µg/ml for 16 hours) and incubated for 4 hours. During incubation, heperanase cleaved soluble complexes containing biotinylated HSGAG bound to VEGF (which complexes are derived from the first plate) were bound to the anti-VEGF coated plate. After washing, the presence of biotinylated HSGAG bound to the anti-VEGF well was detected with avidin peroxidase followed by addition of peroxidase substrate.

The results are shown in the following Table 3 which also includes results for Background and Controlled Experiments as detailed in the Table.

Table 3

Experiment	Procedure	OD 450nm
Invention	(+heparanase + VEGF + anti-VEGF)	0.168
Background	(no heparanase, no VEGF, no anti-VEGF coat)	0.083
Control 1	(no heparanase + VEGF + anti VEGF)	0.097
Control 2	(+heparanase, no VEGF, no anti-VEGF)	0.095

It will be seen from the above results that the procedure of the invention resulted in capture of the cleaved complex of VEGF and biotinylated HSGAG by anti-VEGF antibodies, with detection of the cleaved complex by avidin-peroxidase.

CLAIMS

1. A method of assaying a sample to determine heparanase activity thereof the method comprising

- (i) incubating the sample in the presence of a first solid phase support having immobilised thereon a heparan sulphate glycosaminoglycan (HSGAG) polymer substrate for the heparanase, the said substrate being insensitive to the action of proteases and the said substrate having bonded thereto a first binding moiety and having further bonded thereto a paracrine cell regulator capable of binding to HSGAG;
- (ii) treating the incubated sample with a second solid phase support having a second moiety provided thereon capable of immobilising HSGAG polymer substrate cleaved from the first solid phase support on said second solid phase support by binding of said second moiety either with the paracrine cell regulator or with the first binding moiety;
- (iii) generating a measurable signal from the other of the first or second moiety of the cleaved substrate immobilised on the second support solid phase, and
- (iv) measuring the signal on the second solid phase support separated from the first solid phase support.

2. A method as claimed in claim 1 wherein the HSGAG polymer substrate is covalently bonded to the first solid phase support system.

3. A method as claimed in claim 1 or 2 wherein the first solid phase support system is a microtitre well.

4. A method as claimed in claim 3 wherein the second solid phase support system is a plate lid probe.
5. A method as claimed in claim 3 wherein the second solid phase support system is a microtitre well.
6. A method as claimed in any of claims 1 to 5 wherein the second solid phase support system is separated from the first solid phase support system between steps (ii) and (iii).
7. A method as claimed in any one of claims 1 to 6 wherein, in step (ii), HSGAG polymer substrate cleaved from the first solid phase support is immobilised in the second solid phase support by binding of the first and second moieties.
8. A method as claimed in claim 7 wherein the first moiety is biotin and the second moiety is streptavidin.
9. A method as claimed in claim 7 or 8 wherein the signal is generated by an anti-paracrine cell regulator antibody and enzyme coupled anti-species antibody.
10. A method as claimed in claim 9 wherein the signal is developed by incubating the second solid phase support with anti-paracrine cell regulator antibody followed by peroxidase anti-species IgG.
11. A method as claimed in any one of claims 1 to 6 wherein, in step (ii), the HSGAG polymer substrate cleaved from the first solid phase support is immobilised on the second solid phase support by binding of the paracrine cell regulator and the first moiety.
12. A method as claimed in claim 11 wherein the signal is generated by an enzyme coupled to a third moiety capable of binding to the first moiety.

13. A method as claimed in any one of claims 1 to 12 wherein the paracrine cell regulator is a growth factor, a cytokine or a chemokine.
14. A method as claimed in claim 13 wherein the paracrine cell regulator is a growth factor and is selected from VEGF, TGF β 1, FGF-1, FGF-2, HGF and PDGF.
15. A method as claimed in any of claims 1 to 14 for determining the activity of a putative inhibitor of heparanase activity.
16. A solid phase support having immobilised thereon an HSGAG polymer substrate having bonded thereto a first binding moiety and a paracrine cell regulator capable of binding to HSGAG, said first moiety or said paracrine cell regulator being capable of binding to a second moiety.
17. A support as claimed in claim 16 wherein the paracrine cell regulator is a growth factor, chemokine or cytokine.
18. A support as claimed in claim 17 wherein the paracrine cell regulator is selected from VEGF, TGF β 1, FGF-1, FGF-2, HGF, PDGF, IL-1 α , IL-1 β , IL-2, IL-4, IL-7, IL-8, IL-12, IP-10, MCP-1, TNF α or IFN- α .
19. A support as claimed in any one of claims 16 to 18 wherein the first moiety is biotin.
20. The combination of a solid phase support as claimed in any one of claims 16 to 19 and a second solid phase support having provided thereon said second moiety.
21. An assay kit comprising the combination as claimed in claim 20 and signal developing agents to generate a signal representative of the result of the assay.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 December 2000 (21.12.2000)

PCT

(10) International Publication Number
WO 00/77241 A3(51) International Patent Classification⁷: G01N 33/52,
C12Q 1/34Ernest, Charles [GB/GB]; 5 Dunchurch, Sale, Cheshire
M33 5ED (GB).

(21) International Application Number: PCT/GB00/02117

(74) Agent: ATKINSON, Peter, Birch; Marks & Clerk, Sussex
House, 83-85 Mosley Street, Manchester M2 3LG (GB).

(22) International Filing Date: 12 June 2000 (12.06.2000)

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English


(30) Priority Data:
9913415.7 10 June 1999 (10.06.1999) GB(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (for all designated States except US): CENTRAL MANCHESTER HEALTHCARE NHS TRUST
[GB/GB]; Cobbett House, Manchester Royal Infirmary,
Oxford Road, Manchester M13 9WL (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): BRENCHLEY, Paul,

[Continued on next page]

(54) Title: HEPARANASE ASSAY



WO 00/77241 A3



(57) Abstract: A method of assaying a sample to determine heparanase activity thereof comprises the steps of (i) incubating the sample in the presence of a first solid phase support having immobilised thereon an HSGAG polymer substrate for the heparanase, the said substrate being insensitive to the action of proteases and the said substrate having bonded thereto a first binding moiety and having further bonded thereto a paracrine cell regulator capable of binding to HSGAG, (ii) treating the incubated sample with a second solid phase support having a second moiety provided thereon capable of immobilising HSGAG polymer substrate cleaved from the first solid phase support on said second solid phase support by binding of said second moiety either with the paracrine cell regulator or with the first binding moiety, (iii) generating a measurable signal the other of the first or second moiety of the cleaved substrate immobilised in the second support solid phase, and (iv) measuring the signal on the second solid phase support separated from the first solid phase support.

WO 00/77241

PCT/GB00/02117

1 / 1


10/018260

FIG 1FIG 2

**DECLARATION AND POWER OF
ATTORNEY
FOR PATENT APPLICATION**

Attorney Docket Number	7397-3
First Named Inventor	Paul Ernest Charles Brenchley
COMPLETE IF KNOWN	
Application No.	10/018,260
Filing Date	Dec. 7, 2001
Group Art Unit	
Examiner's Name	

Declaration submitted with Initial Filing



Declaration Submitted after Initial Filing surcharge (37 CFR 1.16(e)) required

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

HEPARANASE ASSAY

the specification of which
(check one)

- is attached hereto.
- Was filed on June 12, 2000 as United States Application No. or
PCT International Application No. PCT/GB00/02117
- And was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YY)	Priority Not Claimed	Certified Copy Attached?	
				Yes	No
GB00/02117	PCT	06/12/2000		<input type="checkbox"/>	<input checked="" type="checkbox"/>
9913415.7	GB	06/10/1999		<input type="checkbox"/>	<input checked="" type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.


Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.	

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

Additional US or PCT International application numbers are listed on a supplement priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:



Name	Registration Number	Name	Registration Number
Thomas Q. Henry	28,309 (37)		

<input checked="" type="checkbox"/>	Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.		
-------------------------------------	---	--	--

Direct all correspondence to : Customer Number Bar Code Label OR Correspondence address below

Name	Thomas Q. Henry		
Firm Name	WOODARD EMHARDT NAUGHTON MORIARTY & McNETT		
Address	111 Monument Circle, Bank One Tower Suite 3700		
Address			
City	Indianapolis	State	IN
Country	USA	Telephone	317/ 634-3456
		ZIP	46204
		Fax	317-637-7561

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor:			
Given Name (first and middle, if any)	Paul Ernest Charles	Family Name or Surname	Brenchley
Inventor's Signature:	<i>PEB</i>	Date of Signature:	7/03/2002
Residence: (City, State, Country)	Sale, Cheshire, United Kingdom C BX		
Citizenship:	GB		
Post Office Address:	5 Dunchurch Sale, Cheshire, M33 5ED, United Kingdom		

DECLARATIONRegistered Practitioner Information
(Supplemental Sheet)

Name	Registration Number	Name	Registration Number
Harold R. Woodard	16,214		
C. David Emhardt	18,483		
Joseph A. Naughton, Jr.	19,814		
John V. Moriarty	26,207		
John C. McNett	25,533		
Thomas Q. Henry	28,309		
James M. Durlacher	28,840		
Charles R. Reeves	28,750		
Vincent O. Wagner	29,596		
Steve Zlatos	30,123		
Spiro Bereveskos	30,821		
Clifford W. Browning	32,201		
R. Randall Frisk	32,221		
Daniel J. Lueders	32,581		
Kenneth A. Gandy	33,386		
Timothy N. Thomas	35,714		
Kurt N. Jones	37,237		
John H. Allie	39,088		
Holiday W. Banta	40,311		
Troy J. Cole	35,102		
L. Scott Paynter	39,797		
Charles J. Meyer	41,996		
Matthew R. Schantz	40,800		
Gregory B. Coy	40,967		
Lisa A. Hiday	40,036		
John V. Daniluck	40,581		
Christopher A. Brown	41,642		
C. John Brannon	44,557		
Arthur J. Usher IV	41,359		
Douglas A. Collier	43,556		
Brad A. Schepers	45,431		
Scott J. Stevens	29,446		
James B. Myers	42,021		
John M. Bradshaw	46,573		
Charles P. Schmal	45,082		
Edward E. Sowers	36,015		

12/01